Strong Results with 38.1% Revenue Growth Lifted Glaukos (GKOS) in Q4

2 weeks ago 17

Soumya Eswaran

Mon, February 23, 2026 astatine 7:28 AM CST 4 min read

Brown Capital Management, an concern absorption company, released its 4th fourth 2025 capitalist missive for “The Brown Capital Management Small Company Fund”. A transcript of the missive tin beryllium downloaded here. In the 4th fourth of 2025, the Small Company Fund (Investor shares) fell 1.50%, down the Russell 2000® Growth index's 1.22% gain. Real property and telecommunications businesses led the benchmark's show for the quarter. The Fund was down 11.46% successful 2025, importantly lagging the Index’s 13.01% return. The firm’s concern decisions are driven by institution fundamentals, and its holdings performed good successful presumption of gross and net maturation successful 2025. Please reappraisal the Fund’s apical 5 holdings to summation insights into their cardinal selections for 2025.

In its fourth-quarter 2025 capitalist letter, The Brown Capital Management Small Company Fund highlighted stocks similar Glaukos Corporation (NYSE:GKOS). Glaukos Corporation (NYSE:GKOS) is an ophthalmic pharmaceutical and aesculapian exertion institution that focuses connected the attraction of glaucoma. The one-month instrumentality of Glaukos Corporation (NYSE:GKOS) was -3.22%, and its shares mislaid 3.20% of their worth implicit the past 52 weeks. On February 20, 2026, Glaukos Corporation (NYSE:GKOS) banal closed astatine $120.27 per share, with a marketplace capitalization of $6.908 billion.

The Brown Capital Management Small Company Fund stated the pursuing regarding Glaukos Corporation (NYSE:GKOS) successful its 4th fourth 2025 capitalist letter:

"Among the contributors to show successful the 4th fourth of 2025 was Glaukos Corporation (NYSE:GKOS). Glaukos is simply a medical-device institution that specializes successful the attraction of glaucoma. The institution offers a suite of products specified arsenic iStent, Infinite, iDose and others. iStent is simply a imperishable stent designed to dainty glaucoma by opening the drainage canal and lowering intraocular pressure. The astir caller iStent product, Infinite, allows aggregate stents to beryllium utilized to dainty glaucoma arsenic a standalone procedure. iDose is simply a tiny implant that allows for the continuous transportation of drugs to dainty glaucoma. iDose was approved by the FDA successful December 2023 and has proven to beryllium a existent paradigm displacement successful glaucoma treatment.

Read Entire Article